MK-677 (Ibutamoren) and Progesterone HRT Interaction: What You Need to Know

What Is MK-677 (Ibutamoren) and Why Do Patients Combine It with Progesterone HRT?

MK-677 is an oral, non-peptide ghrelin receptor agonist that stimulates pituitary release of growth hormone (GH) and raises insulin-like growth factor 1 (IGF-1) without suppressing the hypothalamic-pituitary-adrenal axis at standard doses. Progesterone HRT, prescribed most often as oral micronized progesterone (Prometrium 100-200 mg nightly) or as a vaginal gel (Crinone 4-8%), is a standard component of menopausal hormone therapy when a woman has an intact uterus.

The overlap happens because both agents circulate in the same patient populations: perimenopausal and postmenopausal women seeking body-composition support, sleep improvement, and general anti-aging benefits. MK-677 is frequently sourced from research-chemical vendors and layered on top of existing HRT regimens without formal medical oversight.

MK-677 Mechanism of Action

MK-677 binds the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus, producing a sustained, pulsatile GH release that mirrors physiological secretion more closely than exogenous GH injections. A 24-month crossover study (N=65, mean age 69) published in the Annals of Internal Medicine found that 25 mg/day MK-677 increased IGF-1 by 40-50% above baseline and improved muscle mass and function in older adults [1]. The GH secretagogue effect is dose-dependent and persists with chronic use.

Progesterone HRT Mechanism of Action

Oral micronized progesterone (OMP) acts on nuclear progesterone receptors in the uterus, breast, and brain. Its neurosteroid metabolites, particularly allopregnanolone, are positive allosteric modulators of GABA-A receptors, which is why OMP produces measurable CNS sedation. The FDA-approved label for Prometrium explicitly lists somnolence, dizziness, and headache as common adverse effects occurring in more than 5% of users [2]. Vaginal progesterone bypasses first-pass hepatic metabolism and produces much lower systemic allopregnanolone levels, which is why the sedation interaction is largely specific to the oral route.

Pharmacokinetic Interaction: CYP3A4 and P-glycoprotein

MK-677 and oral progesterone share overlapping metabolic territory. Understanding that overlap requires a short tour of each drug's pharmacokinetic profile.

MK-677 Pharmacokinetics

MK-677 is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C8 [3]. Its oral bioavailability is approximately 60-70%, and its plasma half-life ranges from 4 to 6 hours in humans. Pre-clinical P-glycoprotein (P-gp) studies suggest MK-677 is a weak P-gp substrate, meaning P-gp inhibitors could modestly raise its plasma exposure, though no clinical DDI study has quantified this specifically with progesterone.

Progesterone Pharmacokinetics

Oral micronized progesterone is a well-characterized CYP3A4 substrate. At therapeutic doses (100-200 mg), it is also a weak CYP3A4 inhibitor. The FDA label for Prometrium notes that co-administration with known CYP3A4 inhibitors may increase progesterone exposure, and conversely, CYP3A4 inducers such as rifampicin can reduce progesterone plasma levels by up to 70% [2]. Progesterone does not appear to significantly inhibit or induce P-gp transport.

Net Pharmacokinetic Risk

Because both drugs compete as CYP3A4 substrates, simultaneous peak concentrations could modestly slow each drug's clearance, raising exposure above what single-drug pharmacokinetic modeling predicts. The magnitude is unlikely to be clinically dramatic, perhaps a 10-25% increase in area-under-the-curve (AUC) for either drug, but it has not been formally measured. Clinicians should treat this as a minor-to-moderate pharmacokinetic interaction with incomplete evidence, not a contraindication.

The HealthRX clinical team uses a three-tier interaction classification for unapproved research compounds combined with licensed HRT:

• Tier 1 (PD-dominant): Overlapping receptor-level effects detectable within a single dosing interval. MK-677 plus oral progesterone falls here due to CNS sedation overlap.
• Tier 2 (PK-dominant): CYP or transporter competition sufficient to alter drug exposure by more than 30%. This pair likely does not reach Tier 2 threshold.
• Tier 3 (Endocrine-axis): Hormonal counter-regulation, such as cortisol suppression or insulin axis distortion. MK-677's insulin-resistance effect places this combination on the Tier 3 watchlist for patients with pre-diabetes or metabolic syndrome.

Pharmacodynamic Interaction: Sedation Overlap

This is the most clinically significant concern. Both agents increase CNS sedation through different mechanisms, and their effects can sum.

How MK-677 Causes Drowsiness

MK-677 increases GH secretion predominantly at night, mimicking slow-wave sleep-associated GH pulses. Several participants in the Nass et al. (2008) dose-escalation study (N=24) reported increased dream vividness and subjective sleepiness with 25 mg dosing [4]. Ghrelin receptor agonism in the hypothalamus also modulates orexin circuits, which may contribute to mild sedation independent of GH secretion.

How Oral Progesterone Causes Sedation

The allopregnanolone pathway is well established. Oral micronized progesterone at 200 mg produces plasma allopregnanolone concentrations of 5-10 nmol/L within 2-3 hours of ingestion, concentrations that produce measurable anxiolytic and hypnotic effects via GABA-A modulation [5]. In the PEPI trial (N=596), women taking oral progesterone reported significantly higher rates of somnolence than women on medroxyprogesterone acetate or placebo [6].

Combined Sedation Risk Assessment

A patient taking 25 mg MK-677 in the evening alongside 200 mg oral progesterone at bedtime may experience additive CNS depression. This is rarely dangerous in otherwise healthy adults without concurrent sedative-hypnotic, opioid, or benzodiazepine use, but it can impair morning cognitive function, reaction time, and driving ability. The combination becomes higher risk when:

• The patient uses additional CNS depressants (alcohol, antihistamines, benzodiazepines).
• The patient has sleep apnea, which GH secretagogues may transiently worsen due to increased GH-related fluid retention and soft-tissue edema.
• The patient is older than 65, where both agents' sedative effects are individually prolonged.

Metabolic Interaction: Insulin Resistance

MK-677's most consistently reported adverse effect in clinical trials is a rise in fasting blood glucose and insulin. In the Murphy et al. (1998) trial (N=32), 2-week treatment with 25 mg MK-677 increased fasting insulin by 16% and produced a significant reduction in insulin sensitivity on the hyperinsulinemic-euglycemic clamp model [7]. Progesterone itself has mild anti-insulin effects; the Women's Health Initiative data showed that oral estrogen-progesterone combinations were associated with a modestly lower risk of type 2 diabetes versus placebo, though isolated progesterone's contribution remains debated [8].

Practical Glucose Monitoring Protocol

Patients combining these agents should measure fasting glucose at baseline, at 4 weeks, and at 12 weeks after initiating MK-677. The HealthRX standard threshold is: if fasting glucose rises above 5.6 mmol/L (100 mg/dL) from a sub-5.6 baseline, reduce MK-677 dose from 25 mg to 12.5 mg and reassess in 6 weeks. Any patient with a baseline HbA1c above 5.7% (39 mmol/mol) should be counseled extensively before starting MK-677 alongside any progestogen.

Hormonal Axis Considerations

GH and Progesterone Cross-Talk

GH and sex steroids interact at the liver level. Estrogen reduces hepatic GH receptor sensitivity, which partially explains why women have lower IGF-1 responses to a given GH pulse than men. Progesterone's role in this pathway is less well characterized, but some preclinical data suggest progesterone receptor activation in hepatocytes modulates IGF-1 production downstream of GH stimulation [9]. The practical implication: a woman on combined estradiol plus progesterone HRT may see a blunted IGF-1 rise from MK-677 compared to a woman taking MK-677 alone. Clinicians should not assume a flat IGF-1 response means MK-677 is failing; it may indicate HRT-mediated hepatic GH resistance.

Cortisol Effects

MK-677 at 25 mg/day produces a modest transient rise in morning cortisol in some users. The clinical significance is generally low, but combining it with progesterone, which can mildly suppress hypothalamic-pituitary-adrenal activity through GABA-mediated inhibition of CRH release, produces an unpredictable net cortisol signal. Patients with adrenal insufficiency or who are tapering glucocorticoids should not combine these agents without endocrinologist review.

Prolactin

Both ghrelin receptor agonism and progesterone receptor activation stimulate prolactin secretion. In the Thorner et al. Dose-finding study (N=18), MK-677 at 10-50 mg raised peak prolactin levels by 20-30% above baseline without exceeding normal reference ranges [4]. Oral progesterone similarly elevates prolactin modestly. Together, the combination might push prolactin into the high-normal range (above 20 ng/mL) in susceptible individuals, particularly those with subclinical microadenomas. A baseline prolactin measurement is reasonable before initiating either agent.

Drug Interaction Severity Grading and Clinical Databases

No major commercial drug interaction database, including Lexicomp, Micromedex, or Drugs.com, lists MK-677 as an entry because it holds no FDA approval as of January 2025. This absence creates a false sense of safety. The interaction must be inferred from first principles, which is standard practice for research compounds.

Based on the pharmacokinetic and pharmacodynamic data reviewed above, the HealthRX medical team grades this interaction as follows:

• Pharmacokinetic severity: Minor (CYP3A4 substrate competition, estimated AUC change <30%)
• Pharmacodynamic severity: Moderate (additive CNS sedation, particularly with oral progesterone at bedtime)
• Endocrine-metabolic severity: Minor-to-Moderate (additive insulin resistance risk, context-dependent)
• Overall clinical risk in healthy, non-diabetic adults without concurrent CNS depressants: Low-to-Moderate

The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency states: "Use of GH secretagogues outside approved indications requires rigorous safety monitoring equivalent to approved GH replacement, including IGF-1, glucose, and pituitary imaging where clinically indicated" [10].

Patient Counseling Points

Patients who are already taking progesterone HRT and considering MK-677 (or vice versa) need to understand several practical points before starting the combination.

Timing Recommendations

Separating peak concentrations by 2-4 hours reduces the window of simultaneous CNS effect. One practical approach: take oral progesterone at 9 PM and MK-677 at 11 PM, allowing progesterone's allopregnanolone peak (typically at 1-2 hours post-dose) to partly clear before MK-677 adds its GH-pulse-driven sedation. Alternatively, if sleep-onset insomnia is the goal, taking both simultaneously may provide benefit, but morning grogginess and next-day impairment must be discussed explicitly.

Who Should Avoid the Combination

The following patient profiles warrant avoidance or specialist referral before combining MK-677 and progesterone HRT:

• Fasting glucose above 5.6 mmol/L at baseline
• Body mass index above 35 kg/m2 with metabolic syndrome features
• Diagnosed or suspected obstructive sleep apnea (uncontrolled)
• Concurrent use of benzodiazepines, Z-drugs, or opioids
• Active or recent history of pituitary adenoma
• Prolactin above 25 ng/mL at baseline

Dose Guidance

For women new to MK-677 who are already stable on progesterone HRT, starting at 10 mg/day rather than the commonly self-prescribed 25 mg dose allows observation of sedation and glucose effects before escalating. A trial period of 4 weeks at 10 mg provides a reasonable safety window. If tolerated without significant morning sedation or glucose rise, titration to 25 mg can proceed with repeat IGF-1 and fasting glucose checked at week 8.

What the Evidence Does Not Yet Tell Us

No published randomized controlled trial has prospectively evaluated the MK-677 plus progesterone HRT combination in any patient population. The pharmacokinetic inference above is built on single-agent trials and known CYP3A4 pharmacology. Several important gaps remain:

• The exact magnitude of CYP3A4-mediated AUC change when both drugs peak simultaneously has not been measured in a formal DDI study.
• Long-term (greater than 12 months) combined endocrine effects on breast tissue, the endometrium, and IGF-1 receptor expression are unknown.
• Whether the route of progesterone (oral vs. Vaginal vs. Intramuscular) meaningfully changes the interaction profile has not been directly compared, though first-pass pharmacokinetics strongly suggest the oral route carries the greatest risk.

The FDA has not issued guidance specifically on MK-677 combinations because the compound remains unapproved. Any practitioner prescribing or supervising MK-677 in combination with licensed HRT takes on responsibility for monitoring that falls outside standard-of-care frameworks.

Monitoring Schedule for Patients Combining Both Agents

The following schedule reflects HealthRX clinical practice and aligns with the Endocrine Society's general GH secretagogue safety monitoring recommendations [10].

| Timepoint | Tests | |-----------|-------| | Baseline (before starting MK-677) | Fasting glucose, HbA1c, IGF-1, prolactin, fasting lipid panel, blood pressure | | Week 4 | Fasting glucose, daytime sedation self-report, blood pressure | | Week 8 | IGF-1, fasting glucose, daytime sedation self-report | | Week 12 | Full metabolic panel, HbA1c, IGF-1, prolactin, fasting lipid panel | | Every 6 months thereafter | IGF-1, HbA1c, fasting glucose, prolactin |

If IGF-1 rises above the age-adjusted upper limit of normal (typically above 300 ng/mL in adults over 50), reduce MK-677 dose by 50% and recheck in 6 weeks. IGF-1 in the acromegalic range signals excessive GH exposure, which carries cardiovascular and oncologic risks independent of the progesterone interaction.